Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)

NCT01453634 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The company is no longer pursuing this study.

Conditions

Stage 5 Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Hemodialysis (HD)

Interventions

DRUG: Lunacalcipol 180
DRUG: Lunicalcipol 270

Sponsor

OPKO Health, Inc.